Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SH) has announced that its wholly-owned subsidiary, China State Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., recently received a Drug Registration Certificate for Bisoprolol Amlodipine Tablets from the National Medical Products Administration.
Bisoprolol Amlodipine Tablets are indicated as a replacement therapy for hypertension treatment, specifically for patients who are currently well-controlled on the same doses of individual medications as those contained in the fixed-dose combination product.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments